>>MSCI – Two additions to MSCI Indonesia: Charoen Pokphand Indonesia (CPIN) and Kalbe Farma (KLBF). Estimated buying volume for CPIN is 43.5mn shares, for KLBF is 133mn shares.>>>
"إِنَّا مَكَّنَّا لَهُۥ فِى ٱلْأَرْضِ وَءَاتَيْنَهُ مِن كُلِّ شَىْءٍۢ سَبَبًۭا فَأَتْبَعَ سَبَبًا Sesungguhnya Kami telah memberi kekuasaan kepadanya di (muka) bumi, dan Kami telah memberikan kepadanya jalan (untuk mencapai) segala sesuatu, maka diapun menempuh suatu jalan." (QS. AL KAHFI:84-85)
>> Saham Agung Podomoro Dilepas Rp365 per Unit >>> INDY: After mkt close the major shareholders placed out a USD 200m block of stock, or about 10% of cap at 3675 (range 3600-3725) at a 5.7% discount. The placement was said to be 3X subscribed to.

My Family

Rabu, 28 April 2010

Credit Suisse: Bank Mandiri (BMRI.JK, Rp5350, O, TP Rp6900) - Another sterling quarter

■ Another sterling quarter: BMRI reported 1Q10A net income of Rp2,003 bn, 43% YoY, 22% of our forecasts (versus 1Q09A which contributes 20% of FY09A), and 24% of consensus’ forecasts. BMRI’s 1Q10A PPOP of Rp3,392 bn came 24% of our FY10E expectations.

■ Robust fundamentals: BMRI’s repeat sterling performance provides a very convincing evidence that it is no longer transforming, but rather is a bank with robust fundamentals and growth outlook poised to take the top position in the Indonesian banking sector. BMRI currently exhibits the second lowest LDR with 15.7% 1Q10A CAR, implying significant growth potential ahead. BMRI’s robust fundamentals are well illustrated by its ability to deliver the second highest provision coverage, the second lowest NPL ratio and the third highest ROE of the six Indonesian banks under our coverage.

■ More potential for rerating: Despite its past rerating, we believe BMRI’s current share price does not yet adequately reflect the company’s fundamental strength. BMRI is still trading at 24% and 60% discounts to MSCI Indonesia and MSCI NJA banks, respectively.

■ Undemanding valuations: The large discount against MSCI Indonesia and MSCI NJA banks, despite its fundamentals being stronger than its peers implies that BMRI’s share price still offers an attractive entry point. We maintain our OUTPERFORM rating on BMRI and target price of Rp6,900, implying 3.6x 2010E P/B and 15.8x 2010E P/E. We maintain BMRI as our top pick in the Indonesia banks sector.

Tidak ada komentar:

Posting Komentar

Yahoo! Finance: Top Stories

Reuters: Business News

Insider Stories

CNBC Top News and Analysis

» Ekobiz

The Wall Street Journal

AnggunTraders.com

Commodity Online Metals News

Britama.com

Palm Oil Prices

Commodities-Markets-The Economic Times

Detikfinance

BusinessWeek.com -- Top News

Palm Oil HQ Daily Update

Business Times : marketwatch

VIVAnews - BISNIS

The Star Online: Business

Inilah.com -

Latest financial news - CNNMoney.com

Tempointeraktif.com - Bisnis

ChinaDaily > bizchina

Sindikasi economy.okezone.com

Commodity News

Bursa Rumor - Tempatnya Investor Saham Cari Berita

Financial Times - Financial markets news

Hellenic Shipping News

ANTARA - Ekonomi & Bisnis

Industrial Metals & Minerals Industry News

Republika Online - Ekonomi

Yahoo Commodities News